Central Serous Chorioretinopathy: Update on Pathophysiology and Treatment

By B. Nicholson, J. Noble, F. Forooghian, Catherine B. Meyerle. Survey of ophthalmology, 2013

618 citations recorded by the source corpus.

Recent technological advances have led to an improved understanding of central serous chorioretinopathy (CSC): new pathophysiological insights, new imaging techniques for diagnosis and management, and new treatments. The primary role of the choroid has become more widely accepted with widespread use of indocyanine green angiography. Optical coherence tomography (OCT), and particularly enhanced depth imaging OCT, demonstrate a thickened and engorged choroid. Adaptive optics, fundus autofluorescence, multifocal electroretinography, microperimetry, and contrast sensitivity testing reveal that patients with even a mild course suffer previously undetected anatomic and functional loss. While focal laser and photodynamic therapy are the current standard of care for persistent subretinal fluid in CSC, they are not appropriate in all cases, and the optimal timing of intervention remains unclear.

Subfields: Ophthalmology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/10990442683a631df9be1329f43e2255308be7f3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Daruich
2. A. Matet
3. F. Behar-Cohen
4. Min Zhao
5. E. Bousquet
6. F. Jaisser
7. N. Farman
8. A. Dirani

Citations in the corpus

• Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. (2015, background): “Classically, treatment can be justified in the following indications: persistent macular SRD for at least 4 months, history of multiple recurrences, history of CSCR in the fellow eyewith poor visual outcome, reduced visual acuity, and rapid recovery required (Nicholson et al., 2013).”